VEGF antagonists are widely used to treat not only ARMD but also cancers and other diseases associated with retinal neovascularization, including proliferative diabetic retinopathy, retinal vein occlusion (71), and, “off label,” for retinopathy of prematurity (72). Here, VEGFA is linked to proliferative diabetic retinopathy.